Partners for
good measure
Medtronic has entered into a strategic partnership with CathWorks with path toward acquisition
Highlights of a successful TCT 2022
Learn why FFRangio is poised to become the new standard of care in physiology assessment
Regulatory approval
in Japan
The 4th generation CathWorks FFRangio® System has been approved by the PMDA
1st FFRangio Case at South Shore Health
Congratulations to
Dr. Anthony Litvak and team for performing their first FFRangio case
Now, interventional cardiologists in the cath lab can see the full picture of their patient’s physiology.
The FFRangio System combines artificial intelligence and advanced computational science to obtain physiologic information from routine angiograms to better inform treatment decisions.
Treat confidently with the FFRangio System
1%
Diagnostic Accuracy
1%
Sensitivity
1%
Specificity
The FFRangio System consistently demonstrates excellent diagnostic performance compared to traditional invasive FFR wires across a wide spectrum of patients and lesion subgroups.1
FFRangio System Insights
FFRangio System: A New Era in Coronary Physiology
At TCT 2022, panel experts Dr. Martin B. Leon, Prof. Ran Kornowski, Dr. Rahul P. Sharma and Dr. Amir Kaki shared how they integrated the CathWorks FFRangio System in their cath labs and explained why it’s poised to be the new standard of care in physiology assessment.
Clinical Outcomes of Angiogram-Based FFR Guided Treatment of CAD
At ACC 2022, Dr. Guy Witberg from Rabin Medical Center presented the first outcomes study demonstrating the safety of managing patients clinically based on the CathWorks FFRangio System results.
1. Witberg G, De Bruyne B, Fearon WF, et al. Diagnostic performance of angiogram-derived fractional flow reserve: A pooled analysis of 5 prospective cohort studies. J Am Coll Cardiol Intv.2020;13(4):488-97.